Marco Ruella
15Patents
5h-index
46Co-inventors
58Inventor score
Filing activity: Apr 7, 2015 → Mar 28, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9815901B2 | Treatment of cancer using a CD123 chimeric antigen receptor | Chemistry; Metallurgy | 80 | Active |
| US10174095B2 | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor | Chemistry; Metallurgy | 27 | Active |
| US10253086B2 | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell | Chemistry; Metallurgy | 20 | Active |
| US11084880B2 | Anti-BCMA chimeric antigen receptor | Chemistry; Metallurgy | 8 | Active |
| US10357514B2 | Treatment of cancer using anti-CD19 Chimeric Antigen Receptor | Chemistry; Metallurgy | 7 | Active |
| US11149076B2 | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell | Chemistry; Metallurgy | 5 | Active |
| US11026976B2 | Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain | Chemistry; Metallurgy | 2 | Active |
| US11673964B2 | Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias | Chemistry; Metallurgy | 1 | Active |
| US11872249B2 | Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain | Chemistry; Metallurgy | 0 | Active |
| US12214037B2 | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor | Chemistry; Metallurgy | 0 | Active |
| USRE49847E1 | Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain | General | 0 | Active |
| US12227588B2 | Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias | Chemistry; Metallurgy | 0 | Active |
| US12344657B2 | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell | Chemistry; Metallurgy | 0 | Active |
| US11591404B2 | Treatment of cancer using a CD123 chimeric antigen receptor | Chemistry; Metallurgy | 0 | Active |
| US10703819B2 | Treatment of cancer using a CD123 chimeric antigen receptor | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.